ClinicalTrials.gg
CompletedNCT04871113Updated Oct 15, 2024Results posted

A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults

A Phase 2 interventional study of GSK3810109A and Dolutegravir+lamivudine SOC regimen in HIV Infections, sponsored by ViiV Healthcare. Completed at 24 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Enrollment
115th of 210
62 · median 82
Started
2021
with 6 others
Phase 2
48 of 266
2 open now
Registered
222nd of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 115th largest by enrollment of the 210 interventional ones that give a count, is one of 7 that started in 2021, is one of 48 in phase 2, and was the 222nd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study is to evaluate antiviral activity, efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GSK3810109A in HIV-1 infected treatment naive adults. Participants will receive a single dose of GSK3810109A administered either intravenously (IV) or subcutaneously (SC). The study includes a screening phase, a randomized monotherapy phase and a standard of care follow-up phase.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Antiretroviral-naïve
  • Broadly neutralizing antibody
  • GSK3810109A
  • HIV
  • N6LS
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 65 years of age inclusive, at the time of signing the .
  • Participants must have -1 infection within 45 days of the Screening Visit: Plasma HIV-1 RNA greater than or equal to (>=) 5000 copies/mL (c/mL).
  • Confirmed screening >= 350 cells per cubic millimeter (cells/mm3).
  • Antiretroviral naïve: No Antiretroviral therapy (ARTs) (in combination or monotherapy) received after the diagnosis of HIV-1 infection.
  • Body weight >= 50 kg to less than or equal to (\<=) 115 kg.
  • Male and/or female. use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. All participants participating in the study should be counselled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g. male condom) and on the risk of HIV transmission to an uninfected partner; a. Participants who are female at birth are eligible to participate if at least one of the following conditions applies: Not Pregnant or breastfeeding and at least one of the following conditions applies: Is not a participant of (POCBP). OR Is a POCBP and using an acceptable contraceptive method during the intervention period (at a minimum until after the last dose of study intervention). The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. A POCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) on Day 1, prior to the first dose of study intervention. If a urine test cannot be confirmed as negative (example [e.g.], an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
  • interval (QTc) Interval \<= 450 milliseconds (msec)
  • Capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Participants with primary infection, evidenced by acute retroviral syndrome (e.g., fever, malaise, fatigue, etc) and/or evidence of recent (within 3 months) documented viremia without antibody production and/or evidence of recent (within 3 months) documented seroconversion.
  • Participants who are pregnant, breastfeeding, plan to become pregnant or breastfeed during the study.
  • The participant has an underlying skin disease or disorder (example i.e. infection, inflammation, dermatitis, eczema, drug rash, drug allergy, psoriasis, food allergy, urticaria) that would interfere with assessment of injection sites.
  • Known history of cirrhosis with or without viral hepatitis co-infection.
  • History of hepatitis within last 6 months.
  • Evidence of virus (HBV) infection based on the results of testing at screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), Hepatitis B surface antigen antibody (anti-HBs) and HBV Deoxyribonucleic acid (DNA) as follows: Participants positive for HBsAg are excluded; Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA are excluded. Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and negative for HBV DNA are not excluded.
  • Participants with co-infection.
  • Untreated syphilis infection (positive rapid plasma reagin [RPR] at screening) without documentation of treatment. Participants who are one month post completed treatment are eligible if recruitment is open.

Rescreening is allowed after treatment.

  • Prior receipt of licensed or monoclonal antibody.
  • Any evidence of an active Centers for Disease Control and Prevention (CDC) Stage 3 disease except cutaneous Kaposi's sarcoma not requiring systemic therapy.
  • Known or suspected moderate or severe hepatic impairment (Class C as determined by Classification) coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • Clinically significant cardiovascular disease, as defined by history/evidence of congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease at the discretion of the investigator.
  • Ongoing other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical, anal or penile intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the study medical monitor for inclusion of the participant prior to randomization.
  • Any pre-existing physical or mental condition which, in the opinion of the investigator, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations, or which may compromise the safety of the participant.
  • Participants with substance abuse disorders or social restraints that the investigator considers to be possible deterrents to successful completion of the study.
  • Participants who in the investigator's judgment, pose a significant suicidality risk. Participants' history of suicidal behavior and/or suicidal ideation should be considered when evaluating for suicide risk.
  • History of sensitivity to any of the study medications or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
  • Any condition which, in the opinion of the investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs, combination ART or render the participant unable to take oral medication.
  • Participants with a positive Corona Virus Disease 2019 (COVID-19) test at Screening. Participants with known COVID-19 positive contacts within the past 14 days, or with symptoms suggestive of active COVID-19 (fever, cough, myalgias, shortness of breath, loss of taste or smell), should be excluded. Participants who remain symptom-free for at least 14 days after a COVID-19 exposure are allowed.
  • Has received any HIV-1 immunotherapeutic vaccine or prophylactic vaccine.
  • Treatment with any of the following agents within 28 days of screening: radiation therapy; cytotoxic chemotherapeutic agents; any systemic immune suppressant;
  • Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of IP.
  • Participants receiving any prohibited medication and who are unwilling or unable to switch to an alternate medication.
  • Participant enrolled in a prior or concurrent clinical study that includes a drug intervention within the last 30 days.
  • Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's inclusion in the study of an investigational compound.
  • Any verified Grade 4 laboratory abnormality. A single repeat test is allowed during the Screening period to verify a result.
  • >= 3 times the (ULN).
  • of \<50 mL/minute/1.73 meter\^2) via Chronic Kidney Disease Epidemiology Collaboration () method.
  • The participant has a tattoo or other dermatological condition overlying potential injection sites which may interfere with interpretation of injection site reactions or administration of GSK3810109A.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Part 1:GSK3810109A 40milligram(mg)/kilogram intravenously (IV)

    Participants with human immunodeficiency viruses-1 (HIV-1) received GSK3810109A as a single intravenous (IV) infusion of 40 milligrams per kilogram (mg/kg) dose based on individual bodyweight on Day 1 in part 1.

    Biological: GSK3810109A

  • Experimental
    Part 1: GSK3810109A 280 mg IV

    Participants with HIV-1 received GSK3810109A as a single IV infusion of 280 mg dose on Day 1 in part 1.

    Biological: GSK3810109A

  • Experimental
    Part 2: GSK3810109A 700 mg IV

    Participants with HIV-1 received GSK3810109A as a single IV infusion of 700 mg dose on Day 1 in part 2. This included dose level determined based on the data of part 1.

    Biological: GSK3810109A

  • Experimental
    Part 2: GSK3810109A 70 mg IV

    Participants with HIV-1 received GSK3810109A as a single IV infusion of 70 mg dose on Day 1 in part 2. This included dose level determined based on the data of part 1.

    Biological: GSK3810109A

  • Experimental
    Part 2: GSK3810109A 700 mg subcutaneously (SC)

    Participants with HIV-1 received GSK3810109A as a subcutaneous (SC) injection of total 700 mg dose administered as three equally divided SC injections of 2.33 mL each (approximately 7 mL) in quick succession at same time on Day 1 in part 2. This included dose level determined based on the data of part 1.

    Biological: GSK3810109A

  • Experimental
    Standard of care (SOC) - GSK3810109A 40mg/kg IV

    Participants who completed the monotherapy phase of treatment of GSK3810109A 40mg/kg IV entered SOC phase to receive dolutegravir + lamivudine regimen as a SOC treatment on SOC Day 1 if deemed appropriate by the investigator and consistent with local guidelines.

    Biological: Dolutegravir+lamivudine SOC regimen

  • Experimental
    SOC - GSK3810109A 280 mg IV

    Participants who completed the monotherapy phase of treatment of GSK3810109A 280 mg IV entered SOC phase to receive dolutegravir + lamivudine regimen as a SOC treatment on SOC Day 1 if deemed appropriate by the investigator and consistent with local guidelines.

    Biological: Dolutegravir+lamivudine SOC regimen

  • Experimental
    SOC - GSK3810109A 700 mg IV

    Participants who completed the monotherapy phase of treatment of GSK3810109A 700 mg IV entered SOC phase to receive dolutegravir + lamivudine regimen as a SOC treatment on SOC Day 1 if deemed appropriate by the investigator and consistent with local guidelines.

    Biological: Dolutegravir+lamivudine SOC regimen

  • Experimental
    SOC - GSK3810109A 70 mg IV

    Participants who completed the monotherapy phase of treatment of GSK3810109A 70 mg IV entered SOC phase to receive dolutegravir + lamivudine regimen as a SOC treatment on SOC Day 1 if deemed appropriate by the investigator and consistent with local guidelines.

    Biological: Dolutegravir+lamivudine SOC regimen

  • Experimental
    SOC - GSK3810109A 700 mg SC

    Participants who completed the monotherapy phase of treatment of GSK3810109A 700 mg SC entered SOC phase to receive dolutegravir + lamivudine regimen as a SOC treatment on SOC Day 1 if deemed appropriate by the investigator and consistent with local guidelines.

    Biological: Dolutegravir+lamivudine SOC regimen

Interventions

  • BiologicalGSK3810109A

    GSK3810109A available as sterile aqueous solution.

  • BiologicalDolutegravir+lamivudine SOC regimen

    Dolutegravir+lamivudine regimen administered in consistence with investigator input and local guidelines

06

What researchers measure

Primary outcomes

  1. Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase

    Plasma samples were collected for quantitative analysis of plasma HIV-1 RNA. Maximum decline from baseline in plasma HIV-1 RNA were measured in participants. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

    Time frame: Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase

  2. Number of Participants With Adverse Events (AEs) - Monotherapy Phase

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

    Time frame: Up to Day 84 or end of Monotherapy Phase

  3. Number of Participants With Worst-case Maximum Grade 2-4 Increase in Post-baseline Values of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Compared to the Baseline Values - Monotherapy Phase

    Blood samples were collected for the analysis of ALT and AST parameters. The parameters ALT and AST were graded using the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates greater severity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Data of number of participants with 2-4 grade increase at worst-case post-baseline (maximum grade increase post-baseline) is presented. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

    Time frame: Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase

  4. Number of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Findings - Monotherapy Phase

    A 12-lead ECG were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT interval corrected using Fridericia's formula (QTcF) intervals. ECG findings were categorized as normal, abnormal clinically significant (CS) and abnormal not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal (CS and NCS) ECG findings are presented. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

    Time frame: Up to Day 84 or end of Monotherapy Phase

  5. Number of Participants With Grade 2-4 Injection Site Reactions (ISR) - Monotherapy Phase

    Number of participants with grade 2-4 injection site reactions are presented. The ISR were graded using the Division of Acquired immunodeficiency syndrome (DAIDS) criteria Version 2.1 where grades were defined based on numeric criteria as follows Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates more severe condition. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

    Time frame: Up to Day 84 or end of Monotherapy Phase

Secondary outcomes

  1. Area Under the Plasma Concentration-time Curve From Time Zero to the Day 14 (AUC [0-14]) of GSK3810109A - Monotherapy Phase

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3810109A.

    Time frame: Pre-dose (Day 1), 3 and 24 hours post-dose on day 1, days 3, 6, 9, 11, and 14

  2. Maximum Observed Plasma Concentration (Cmax) of GSK3810109A - Monotherapy Phase

    Cmax is defined as maximum observed concentration of GSK3810109A.

    Time frame: Pre-dose (Day 1), 3 and 24 hours post-dose on day 1, days 3, 6, 9, 11, and 14

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax) of GSK3810109A - Monotherapy Phase

    Tmax is defined as time to reach Cmax

    Time frame: Pre-dose (Day 1), 3 and 24 hours post-dose on day 1, days 3, 6, 9, 11, and 14

  4. Plasma Concentration at Day 14 (C14) of GSK3810109A - Monotherapy Phase

    Blood samples were collected at indicated time point for pharmacokinetic analysis of GSK3810109A.

    Time frame: At Day 14

  5. Change From Baseline in Log10 Plasma HIV-1 RNA Relative to Cmax - Monotherapy Phase

    Plasma samples were collected for quantitative analysis of HIV-1 RNA. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. Statistical analysis for relationship between PK parameter (Cmax) and PD measure (change from baseline in logarithm to base 10 (log10) values for plasma HIV-1 RNA) were explored using an Emax non-linear model. The model parameters estimated included: maximum response (Emax), PK parameter value that attains 50 percent (%) of the maximal effect (EC50) and residual variability (s2e). End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

    Time frame: Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase

  6. Absolute Values of Cluster of Differentiation 4 Plus (CD4+) and CD8+ T Cell Counts - Monotherapy Phase

    Blood samples were collected as prespecified. CD4+ and CD8+ T cell counts were assessed using flow cytometry. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

    Time frame: From Day 1 (Baseline) and up to Day 84 or end of Monotherapy Phase

  7. Absolute Values of CD4+ and CD8+ T Cell Counts - SOC Phase

    Blood samples were collected as prespecified. CD4+ and CD8+ T cell counts were assessed using flow cytometry.

    Time frame: Up to Week 48 (SOC Phase)

  8. Change From Baseline in CD4+ and CD8+ T Cell Counts - Monotherapy Phase

    Blood samples were collected as prespecified. CD4+ and CD8+ T cell counts were assessed using flow cytometry. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

    Time frame: Up to Day 84 or end of Monotherapy Phase (compared with baseline [Day 1])

  9. Change From Baseline in CD4+ and CD8+ T Cell Counts - SOC Phase

    Blood samples were collected as prespecified. CD4+ and CD8+ T cell counts were assessed using flow cytometry.

    Time frame: Up to Week 48 (SOC Phase)

  10. Number of Participants With Positive Anti-drug Antibodies (ADAs) Against GSK3810109A - Monotherapy Phase

    Serum samples were collected to analyze the presence of ADAs against GSK3810109A using validated immunoassays. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

    Time frame: At Day 1 and Day 84 or end of Monotherapy Phase

  11. Number of Participants With Positive ADAs Against GSK3810109A - SOC Phase

    Serum samples were collected to analyze the presence of ADAs against GSK3810109A using validated immunoassays.

    Time frame: At Week 48 (SOC Phase)

  12. Titers of Positive ADAs Against GSK3810109A - Monotherapy Phase

    Serum samples were collected to analyze the presence of ADAs against GSK3810109A using validated immunoassays. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

    Time frame: At Day 84 or end of Monotherapy Phase

  13. Titers of Positive ADAs Against GSK3810109A - SOC Phase

    Serum samples were collected to analyze the presence of ADAs against GSK3810109A using validated immunoassays.

    Time frame: At Week 48 (SOC Phase)

07

Results

Posted Nov 18, 2023

Participant flow

62 unique participants were enrolled in the study including one participant that was re-screened. This re-screened participant signed two different informed consent forms, therefore this participant was counted as enrolling twice.

Part1:Monotherapy Phase(up to Day 84)
Participant flow — Part1:Monotherapy Phase(up to Day 84)
MilestonePart 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)SOC - GSK3810109A 40mg/kg IVSOC - GSK3810109A 280 mg IVSOC - GSK3810109A 700 mg IVSOC - GSK3810109A 70 mg IVSOC - GSK3810109A 700 mg SC
Started8600000000
Completed8600000000
Not completed0000000000
Part2:Monotherapy Phase(up to Day 84)
Participant flow — Part2:Monotherapy Phase(up to Day 84)
MilestonePart 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)SOC - GSK3810109A 40mg/kg IVSOC - GSK3810109A 280 mg IVSOC - GSK3810109A 700 mg IVSOC - GSK3810109A 70 mg IVSOC - GSK3810109A 700 mg SC
Started0016161600000
Completed0016161600000
Not completed0000000000
SOC Follow-up (SOC Day 1 to 48 Weeks)
Participant flow — SOC Follow-up (SOC Day 1 to 48 Weeks)
MilestonePart 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)SOC - GSK3810109A 40mg/kg IVSOC - GSK3810109A 280 mg IVSOC - GSK3810109A 700 mg IVSOC - GSK3810109A 70 mg IVSOC - GSK3810109A 700 mg SC
Started0000086161616
Completed0000075141616
Not completed0000011200
Withdrew: Lost to follow-up0000010000
Withdrew: Withdrawal by subject0000001200

Outcome measures

PrimaryMaximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase

Plasma samples were collected for quantitative analysis of plasma HIV-1 RNA. Maximum decline from baseline in plasma HIV-1 RNA were measured in participants. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

Time frame:
Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase
Reported as:
Median · Copies per milliliter (copies/mL)
Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase
Copies per milliliter (copies/mL)Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)
Baseline (Day 1)12258.5 (1351 to 173710)30833.0 (5938 to 104585)25466.0 (7180 to 110387)25689.5 (7225 to 683576)23146.0 (131 to 181078)
Maximum decline from baseline (up to Day 84/end of Monotherapy Phase)-12014.5 (-171577 to -1312)-26826.5 (-103583 to -5899)-25966.0 (-107218 to -6944)-14720.5 (-197793 to -4382)-12584.0 (-178423 to -69)
PrimaryNumber of Participants With Adverse Events (AEs) - Monotherapy Phase

An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

Time frame:
Up to Day 84 or end of Monotherapy Phase
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) - Monotherapy Phase
ParticipantsPart 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)
Number of Participants With Adverse Events (AEs) - Monotherapy Phase749811
PrimaryNumber of Participants With Worst-case Maximum Grade 2-4 Increase in Post-baseline Values of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Compared to the Baseline Values - Monotherapy Phase

Blood samples were collected for the analysis of ALT and AST parameters. The parameters ALT and AST were graded using the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates greater severity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Data of number of participants with 2-4 grade increase at worst-case post-baseline (maximum grade increase post-baseline) is presented. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

Time frame:
Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase
Reported as:
Count of participants · Participants
Number of Participants With Worst-case Maximum Grade 2-4 Increase in Post-baseline Values of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Compared to the Baseline Values - Monotherapy Phase
ParticipantsPart 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)
ALT, Baseline, Grade 086151215
ALT, Baseline, Grade 100121
ALT, Baseline, Grade 200020
ALT, Baseline, Grade 300000
ALT, Baseline, Grade 400000
ALT, Worst Case Post-Baseline, Increase to Grades 2 to 400000
ALT, Worst Case Post-Baseline, Increase to Grades 3 to 400000
AST, Baseline, Grade 086151416
AST, Baseline, Grade 100010
AST, Baseline, Grade 200110
AST, Baseline, Grade 300000
AST, Baseline, Grade 400000
AST, Worst Case Post-Baseline, Increase to Grades 2 to 410101
AST, Worst Case Post-Baseline, Increase to Grades 3 to 410100
PrimaryNumber of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Findings - Monotherapy Phase

A 12-lead ECG were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT interval corrected using Fridericia's formula (QTcF) intervals. ECG findings were categorized as normal, abnormal clinically significant (CS) and abnormal not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal (CS and NCS) ECG findings are presented. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

Time frame:
Up to Day 84 or end of Monotherapy Phase
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Findings - Monotherapy Phase
ParticipantsPart 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)
Abnormal - Clinically Significant00000
Abnormal - Not Clinically Significant32347
PrimaryNumber of Participants With Grade 2-4 Injection Site Reactions (ISR) - Monotherapy Phase

Number of participants with grade 2-4 injection site reactions are presented. The ISR were graded using the Division of Acquired immunodeficiency syndrome (DAIDS) criteria Version 2.1 where grades were defined based on numeric criteria as follows Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates more severe condition. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

Time frame:
Up to Day 84 or end of Monotherapy Phase
Reported as:
Count of participants · Participants
Number of Participants With Grade 2-4 Injection Site Reactions (ISR) - Monotherapy Phase
ParticipantsPart 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)
Number of Participants With Grade 2-4 Injection Site Reactions (ISR) - Monotherapy Phase00000
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Day 14 (AUC [0-14]) of GSK3810109A - Monotherapy Phase

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3810109A.

Time frame:
Pre-dose (Day 1), 3 and 24 hours post-dose on day 1, days 3, 6, 9, 11, and 14
Reported as:
Geometric mean · Day *microgram/millilitre (day*ug/mL)
Area Under the Plasma Concentration-time Curve From Time Zero to the Day 14 (AUC [0-14]) of GSK3810109A - Monotherapy Phase
Day *microgram/millilitre (day*ug/mL)Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)
Area Under the Plasma Concentration-time Curve From Time Zero to the Day 14 (AUC [0-14]) of GSK3810109A - Monotherapy Phase5346.3194 ± 29.6508690.8944 ± 53.27851181.1688 ± 24.4990212.6213 ± 79.1478493.0579 ± 55.0909
SecondaryMaximum Observed Plasma Concentration (Cmax) of GSK3810109A - Monotherapy Phase

Cmax is defined as maximum observed concentration of GSK3810109A.

Time frame:
Pre-dose (Day 1), 3 and 24 hours post-dose on day 1, days 3, 6, 9, 11, and 14
Reported as:
Mean · Microgram/millilitre (μg/mL)
Maximum Observed Plasma Concentration (Cmax) of GSK3810109A - Monotherapy Phase
Microgram/millilitre (μg/mL)Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)
Maximum Observed Plasma Concentration (Cmax) of GSK3810109A - Monotherapy Phase1131.5000 ± 329.91168131.1500 ± 86.65425243.0625 ± 57.3730142.7688 ± 54.3269145.0938 ± 20.48930
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of GSK3810109A - Monotherapy Phase

Tmax is defined as time to reach Cmax

Time frame:
Pre-dose (Day 1), 3 and 24 hours post-dose on day 1, days 3, 6, 9, 11, and 14
Reported as:
Median · Days
Time to Reach Maximum Observed Plasma Concentration (Tmax) of GSK3810109A - Monotherapy Phase
DaysPart 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)
Time to Reach Maximum Observed Plasma Concentration (Tmax) of GSK3810109A - Monotherapy Phase0.0385 (0.024 to 0.125)0.1233 (0.026 to 0.149)0.0340 (0.021 to 0.128)0.0278 (0.003 to 0.994)5.9177 (1.884 to 14.966)
SecondaryPlasma Concentration at Day 14 (C14) of GSK3810109A - Monotherapy Phase

Blood samples were collected at indicated time point for pharmacokinetic analysis of GSK3810109A.

Time frame:
At Day 14
Reported as:
Geometric mean · μg/mL
Plasma Concentration at Day 14 (C14) of GSK3810109A - Monotherapy Phase
μg/mLPart 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)
Plasma Concentration at Day 14 (C14) of GSK3810109A - Monotherapy Phase221.45 ± 23.7627.49 ± 49.2455.30 ± 22.087.98 ± 89.7029.52 ± 54.30
SecondaryChange From Baseline in Log10 Plasma HIV-1 RNA Relative to Cmax - Monotherapy Phase

Plasma samples were collected for quantitative analysis of HIV-1 RNA. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. Statistical analysis for relationship between PK parameter (Cmax) and PD measure (change from baseline in logarithm to base 10 (log10) values for plasma HIV-1 RNA) were explored using an Emax non-linear model. The model parameters estimated included: maximum response (Emax), PK parameter value that attains 50 percent (%) of the maximal effect (EC50) and residual variability (s2e). End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

Time frame:
Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase
Reported as:
Mean · Log10 copies per milliliter (copies/mL)
Change From Baseline in Log10 Plasma HIV-1 RNA Relative to Cmax - Monotherapy Phase
Log10 copies per milliliter (copies/mL)Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IV
Baseline (Day 1)4.139 ± 0.64334.493 ± 0.48004.465 ± 0.35944.582 ± 0.6144
Change from baseline (up to Day 84 or end of Monotherapy Phase)0.091 ± 0.2359-0.357 ± 0.4191-0.110 ± 0.1940-0.179 ± 0.4319
Statistical analysis
  • Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) vs Part 1: GSK3810109A 280 mg IV vs Part 2: GSK3810109A 700 mg IV vs Part 2: GSK3810109A 70 mg IV · Emax: -1.848 · 95% CI -2.225 to -1.472Emax is defined as maximum response.
  • Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) vs Part 1: GSK3810109A 280 mg IV vs Part 2: GSK3810109A 700 mg IV vs Part 2: GSK3810109A 70 mg IV · Ec50: 68.578 · 95% CI 15.866 to 121.290EC50 is defined as the dose (in mg) that attains the 50% of the maximal effect.
  • Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) vs Part 1: GSK3810109A 280 mg IV vs Part 2: GSK3810109A 700 mg IV vs Part 2: GSK3810109A 70 mg IV · S2e: 0.257 · 95% CI 0.145 to 0.368e is defined as random error assumed to be normally distributed with mean zero and constant variance (s2).
SecondaryAbsolute Values of Cluster of Differentiation 4 Plus (CD4+) and CD8+ T Cell Counts - Monotherapy Phase

Blood samples were collected as prespecified. CD4+ and CD8+ T cell counts were assessed using flow cytometry. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

Time frame:
From Day 1 (Baseline) and up to Day 84 or end of Monotherapy Phase
Reported as:
Mean · Cells per cubic milimeter
Absolute Values of Cluster of Differentiation 4 Plus (CD4+) and CD8+ T Cell Counts - Monotherapy Phase
Cells per cubic milimeterPart 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)
CD4+, Baseline (Day 1 (Monotherapy Phase)360.5 ± 166.54412.8 ± 120.85427.3 ± 187.22467.3 ± 194.45476.7 ± 180.28
CD4+, Day 84/end of Monotherapy Phase392.3 ± 196.16443.0 ± 155.17424.0 ± 171.33412.9 ± 98.50462.4 ± 276.72
CD8+, Baseline (Day 1 (Monotherapy Phase)852.0 ± 441.83884.5 ± 389.42781.8 ± 303.751161.3 ± 697.24898.0 ± 348.48
CD8+, Day 84/End of Monotherapy Phase837.9 ± 482.68869.8 ± 376.86744.0 ± 267.73993.1 ± 394.84765.9 ± 296.18
SecondaryAbsolute Values of CD4+ and CD8+ T Cell Counts - SOC Phase

Blood samples were collected as prespecified. CD4+ and CD8+ T cell counts were assessed using flow cytometry.

Time frame:
Up to Week 48 (SOC Phase)
Reported as:
Mean · Cells per cubic milimeter
Absolute Values of CD4+ and CD8+ T Cell Counts - SOC Phase
Cells per cubic milimeterSOC - GSK3810109A 40mg/kg IVSOC - GSK3810109A 280 mg IVSOC - GSK3810109A 700 mg IVSOC - GSK3810109A 70 mg IVSOC - GSK3810109A 700 mg SC
CD4+, Week 48 (SOC Phase)500.5 ± 211.17601.0 ± 44.74580.9 ± 165.29671.3 ± 180.25723.9 ± 300.24
CD8+, Week 48 (SOC Phase)685.9 ± 308.89738.4 ± 213.22684.9 ± 286.60856.0 ± 325.04816.6 ± 364.40
SecondaryChange From Baseline in CD4+ and CD8+ T Cell Counts - Monotherapy Phase

Blood samples were collected as prespecified. CD4+ and CD8+ T cell counts were assessed using flow cytometry. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

Time frame:
Up to Day 84 or end of Monotherapy Phase (compared with baseline [Day 1])
Reported as:
Mean · Cells per cubic milimeter
Change From Baseline in CD4+ and CD8+ T Cell Counts - Monotherapy Phase
Cells per cubic milimeterPart 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)
CD4+, Baseline (Day 1 (Monotherapy Phase)360.5 ± 166.54412.8 ± 120.85427.3 ± 187.22467.3 ± 194.45476.7 ± 180.28
CD4+, Day 84/end of Monotherapy Phase (compared with baseline)31.8 ± 48.2730.2 ± 79.83-3.3 ± 125.78-54.3 ± 121.18-19.6 ± 166.64
CD8+, Baseline (Day 1 (Monotherapy Phase)852.0 ± 441.83884.5 ± 389.42781.8 ± 303.751161.3 ± 697.24898.0 ± 348.48
CD8+, Day 84/end of Monotherapy Phase (compared with baseline)-14.1 ± 213.24-14.7 ± 281.75-37.8 ± 206.05-168.2 ± 401.82-105.7 ± 246.85
SecondaryChange From Baseline in CD4+ and CD8+ T Cell Counts - SOC Phase

Blood samples were collected as prespecified. CD4+ and CD8+ T cell counts were assessed using flow cytometry.

Time frame:
Up to Week 48 (SOC Phase)
Reported as:
Mean · Cells per cubic milimeter
Change From Baseline in CD4+ and CD8+ T Cell Counts - SOC Phase
Cells per cubic milimeterSOC - GSK3810109A 40mg/kg IVSOC - GSK3810109A 280 mg IVSOC - GSK3810109A 700 mg IVSOC - GSK3810109A 70 mg IVSOC - GSK3810109A 700 mg SC
CD4+, Baseline (Day 1 (Monotherapy Phase)360.5 ± 166.54412.8 ± 120.85427.3 ± 187.22467.3 ± 194.45476.7 ± 180.28
CD4+, Week 48 of SOC Phase (compared with baseline)140.0 ± 91.08180.4 ± 114.37134.9 ± 205.13233.8 ± 174.02247.3 ± 230.95
CD8+, Baseline (Day 1 (Monotherapy Phase)852.0 ± 441.83884.5 ± 389.42781.8 ± 303.751161.3 ± 697.24898.0 ± 348.48
CD8+, Week 48 of SOC Phase (compared with baseline)-166.1 ± 274.92-159.4 ± 275.37-119.7 ± 198.49-217.5 ± 490.10-81.4 ± 230.95
SecondaryNumber of Participants With Positive Anti-drug Antibodies (ADAs) Against GSK3810109A - Monotherapy Phase

Serum samples were collected to analyze the presence of ADAs against GSK3810109A using validated immunoassays. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

Time frame:
At Day 1 and Day 84 or end of Monotherapy Phase
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against GSK3810109A - Monotherapy Phase
ParticipantsPart 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)
Baseline (Day 1)00000
Day 84/End of Monotherapy Phase12030
SecondaryNumber of Participants With Positive ADAs Against GSK3810109A - SOC Phase

Serum samples were collected to analyze the presence of ADAs against GSK3810109A using validated immunoassays.

Time frame:
At Week 48 (SOC Phase)
Reported as:
Count of participants · Participants
Number of Participants With Positive ADAs Against GSK3810109A - SOC Phase
ParticipantsSOC - GSK3810109A 40mg/kg IVSOC - GSK3810109A 280 mg IVSOC - GSK3810109A 700 mg IVSOC - GSK3810109A 70 mg IVSOC - GSK3810109A 700 mg SC
Number of Participants With Positive ADAs Against GSK3810109A - SOC Phase00120
SecondaryTiters of Positive ADAs Against GSK3810109A - Monotherapy Phase

Serum samples were collected to analyze the presence of ADAs against GSK3810109A using validated immunoassays. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.

Time frame:
At Day 84 or end of Monotherapy Phase
Reported as:
Median · Titers
Titers of Positive ADAs Against GSK3810109A - Monotherapy Phase
TitersPart 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)
Titers of Positive ADAs Against GSK3810109A - Monotherapy Phase40 (40 to 40)60 (40 to 80)—80 (40 to 640)—
SecondaryTiters of Positive ADAs Against GSK3810109A - SOC Phase

Serum samples were collected to analyze the presence of ADAs against GSK3810109A using validated immunoassays.

Time frame:
At Week 48 (SOC Phase)
Reported as:
Median · Titers
Titers of Positive ADAs Against GSK3810109A - SOC Phase
TitersSOC - GSK3810109A 40mg/kg IVSOC - GSK3810109A 280 mg IVSOC - GSK3810109A 700 mg IVSOC - GSK3810109A 70 mg IVSOC - GSK3810109A 700 mg SC
Titers of Positive ADAs Against GSK3810109A - SOC Phase——40 (40 to 40)160 (160 to 160)—

Adverse events

Collected over All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to 12 weeks for Monotherapy Phase (Part 1 and Part 2 groups) and up to 48 weeks for SOC Phase (SOC groups).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)0/8 (0%)0/8 (0%)7/8 (87.5%)
Part 1: GSK3810109A 280 mg IV0/6 (0%)0/6 (0%)4/6 (66.7%)
Part 2: GSK3810109A 700 mg IV0/16 (0%)0/16 (0%)9/16 (56.3%)
Part 2: GSK3810109A 70 mg IV0/16 (0%)0/16 (0%)8/16 (50%)
Part 2: GSK3810109A 700 mg Subcutaneously (SC)0/16 (0%)0/16 (0%)11/16 (68.8%)
SOC - GSK3810109A 40mg/kg IV0/8 (0%)1/8 (12.5%)8/8 (100%)
SOC - GSK3810109A 280 mg IV0/6 (0%)0/6 (0%)3/6 (50%)
SOC - GSK3810109A 700 mg IV0/16 (0%)3/16 (18.8%)12/16 (75%)
SOC - GSK3810109A 70 mg IV0/16 (0%)2/16 (12.5%)13/16 (81.3%)
SOC - GSK3810109A 700 mg SC0/16 (0%)4/16 (25%)14/16 (87.5%)
Most frequent serious events
Most frequent serious events
EventPart 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)SOC - GSK3810109A 40mg/kg IVSOC - GSK3810109A 280 mg IVSOC - GSK3810109A 700 mg IVSOC - GSK3810109A 70 mg IVSOC - GSK3810109A 700 mg SC
Suicide attemptPsychiatric disorders0/80/60/160/160/161/80/61/160/161/16
AppendicitisInfections and infestations0/80/60/160/160/160/80/61/160/160/16
Scrotal abscessInfections and infestations0/80/60/160/160/160/80/61/160/160/16
Craniocerebral injuryInjury, poisoning and procedural complications0/80/60/160/160/160/80/60/160/161/16
Radius fractureInjury, poisoning and procedural complications0/80/60/160/160/160/80/60/160/161/16
Wrist fractureInjury, poisoning and procedural complications0/80/60/160/160/160/80/60/160/161/16
AnaemiaBlood and lymphatic system disorders0/80/60/160/160/160/80/61/160/160/16
Inguinal herniaGastrointestinal disorders0/80/60/160/160/160/80/60/161/160/16
Human rhinovirus test positiveInvestigations0/80/60/160/160/160/80/60/160/161/16
DehydrationMetabolism and nutrition disorders0/80/60/160/160/160/80/60/161/160/16
Most frequent other events
Showing 10 of 149
Most frequent other events
EventPart 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)SOC - GSK3810109A 40mg/kg IVSOC - GSK3810109A 280 mg IVSOC - GSK3810109A 700 mg IVSOC - GSK3810109A 70 mg IVSOC - GSK3810109A 700 mg SC
COVID-19Infections and infestations1/80/60/162/160/162/80/61/160/160/16
Proctitis gonococcalInfections and infestations0/80/60/160/160/162/80/60/160/160/16
SyphilisInfections and infestations0/81/60/160/160/162/80/60/161/160/16
Upper respiratory tract infectionInfections and infestations0/80/61/160/160/161/80/63/162/162/16
HeadacheNervous system disorders1/80/61/161/163/161/80/60/161/161/16
Abdominal painGastrointestinal disorders1/81/60/160/160/161/80/60/161/160/16
DyspepsiaGastrointestinal disorders0/81/60/160/161/160/80/60/160/160/16
Inguinal herniaGastrointestinal disorders0/80/60/160/160/160/81/60/160/160/16
NauseaGastrointestinal disorders0/81/61/160/161/160/80/60/160/161/16
AstheniaGeneral disorders0/81/60/160/160/160/80/60/160/160/16

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)Total
Mean34.3 ± 9.3934.0 ± 14.8331.2 ± 10.4632.3 ± 10.3331.5 ± 11.0832.2 ± 10.62
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)Total
Female012014
Male8514161558
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV)Part 1: GSK3810109A 280 mg IVPart 2: GSK3810109A 700 mg IVPart 2: GSK3810109A 70 mg IVPart 2: GSK3810109A 700 mg Subcutaneously (SC)Total
American Indian or Alaska Native000213
Black or African American2133211
Native Hawaiian or Other Pacific Islander000101
White - Arabic/ North African Heritage000134
White - White/ Caucasian/ European Heritage65108938
Multiple003115
08

Study locations

24 sites
  • GSK Investigational Site
    Long Beach, California 90813, United States
  • GSK Investigational Site
    Los Angeles, California 90027, United States
  • GSK Investigational Site
    Los Angeles, California 90036, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    Berkley, Michigan 48072, United States
  • GSK Investigational Site
    Manhasset, New York 11030, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Buenos Aires, 1023, Argentina
  • GSK Investigational Site
    Buenos Aires, C1181ACH, Argentina
  • GSK Investigational Site
    Buenos Aires, C1202ABB, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425AGC, Argentina
  • GSK Investigational Site
    Ciudad Autonoma De Bueno, C1405CKC, Argentina
  • GSK Investigational Site
    Mar del Plata, 7600, Argentina
  • GSK Investigational Site
    Rosario, S2000PBJ, Argentina
  • GSK Investigational Site
    San Juan, 5400, Argentina
  • GSK Investigational Site
    Rio de Janeiro, 21045-900, Brazil
  • GSK Investigational Site
    SAo Paulo, 05403-010, Brazil
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2N2, Canada
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
  • GSK Investigational Site
    Regina, Saskatchewan S4P 0W5, Canada
  • GSK Investigational Site
    Merida, 97000, Mexico
  • GSK Investigational Site
    Monterrey, 66278, Mexico
  • GSK Investigational Site
    Lima, Lima 4, Peru
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Oct 2022, 16 months.

Results were first posted in Nov 2023, 1 year after primary completion.

Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 16 months is below that.

Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2021
First posted
May 4, 2021
StartActual
Jun 22, 2021
Primary completionActual
Oct 27, 2022
CompletionActual
Sep 21, 2023
Results first posted
Nov 18, 2023
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04871113
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
May 4, 2021
Start date
Jun 22, 2021
Primary completion
Oct 27, 2022
Completion
Sep 21, 2023
Results posted
Nov 18, 2023
Last update
Oct 15, 2024

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion